Zoetis Inc. (NYSE:ZTS) Shares Bought by Financial Advocates Investment Management

Financial Advocates Investment Management raised its position in Zoetis Inc. (NYSE:ZTSGet Rating) by 82.7% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 4,564 shares of the company’s stock after acquiring an additional 2,066 shares during the quarter. Financial Advocates Investment Management’s holdings in Zoetis were worth $785,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. American National Bank boosted its stake in shares of Zoetis by 469.2% in the 2nd quarter. American National Bank now owns 148 shares of the company’s stock valued at $25,000 after buying an additional 122 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in shares of Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 112 shares during the period. Worth Asset Management LLC purchased a new position in shares of Zoetis in the 1st quarter valued at about $26,000. Aurora Private Wealth Inc. purchased a new position in shares of Zoetis in the 2nd quarter valued at about $36,000. Finally, Capital Wealth Alliance LLC purchased a new position in shares of Zoetis in the 2nd quarter valued at about $45,000. 91.05% of the stock is owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of NYSE ZTS opened at $150.47 on Thursday. The company has a current ratio of 2.27, a quick ratio of 1.48 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a twelve month low of $124.15 and a twelve month high of $249.27. The stock has a 50 day moving average of $148.42 and a two-hundred day moving average of $161.38. The stock has a market cap of $70.13 billion, a P/E ratio of 34.35, a P/E/G ratio of 2.82 and a beta of 0.74.

Zoetis (NYSE:ZTSGet Rating) last issued its quarterly earnings data on Thursday, November 3rd. The company reported $1.21 earnings per share for the quarter, missing analysts’ consensus estimates of $1.24 by ($0.03). Zoetis had a net margin of 25.82% and a return on equity of 48.41%. The firm had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.08 billion. During the same quarter in the prior year, the firm posted $1.25 EPS. Zoetis’s quarterly revenue was up .6% compared to the same quarter last year. On average, research analysts forecast that Zoetis Inc. will post 4.87 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Tuesday, November 1st will be paid a $0.325 dividend. This represents a $1.30 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Monday, October 31st. Zoetis’s dividend payout ratio is currently 29.68%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ZTS shares. Morgan Stanley decreased their price objective on Zoetis from $264.00 to $248.00 and set an “overweight” rating for the company in a research note on Tuesday, November 15th. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Thursday, November 3rd. StockNews.com initiated coverage on Zoetis in a research note on Wednesday, October 12th. They set a “buy” rating for the company. The Goldman Sachs Group decreased their target price on Zoetis from $207.00 to $180.00 and set a “buy” rating for the company in a research note on Friday, November 4th. Finally, JPMorgan Chase & Co. decreased their target price on Zoetis from $250.00 to $225.00 and set an “overweight” rating for the company in a research note on Monday, October 17th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $215.17.

About Zoetis

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.